NCT05514275View on ClinicalTrials.gov

Radiotherapy Combined With Endostatin and Capecitabine for NPC

PHASE2RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2028

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Endostatin and Capecitabine

Patients received radiotherapy Combined With Endostatin(37.5mg/m2, continuous intravenous infusion for 120h, D-7, D8, D22, D36) and Capecitabine( 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles)

Trial Locations (7)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

314000

RECRUITING

the First Hospital of Jiaxing, Jiaxing

315000

RECRUITING

Ningbo First Hospital, Ningbo

RECRUITING

Ningbo Medical Center Lihuili Eastern Hospital, Ningbo

321000

RECRUITING

Jinhua Central Hospital, Jinhua

323000

RECRUITING

The Central Hospital of Lishui City, Lishui

324000

RECRUITING

People's Hospital of Quzhou, Quzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER